Solid Biosciences LLC (SLDB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $763.42M
Last updated: Nov 17, 2026 at 11:05 AM ET
Solid Biosciences LLC (SLDB) Stock Forecast
Analysts expect Solid Biosciences LLC (SLDB) to earn -$1.61 per share in the fiscal year ending Dec 31, 2026. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.64, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 35.7% |
| Buy | 9 | 64.3% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.61
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.59
- EPS consensus, revenue $1.75M
- Next report
- Mar 4, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.61 | -$1.68 to -$1.58 | 12 | N/A | N/A | 11 |
| Dec 31, 2027 | -$1.59 | -$2.14 to -$1.34 | 14 | $1.75M | N/A | 12 |
Quarterly Estimates
The EPS consensus is -$0.41 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.51 to -$0.36 | 16 |
| Mar 31, 2027 | -$0.41 | -$0.53 to -$0.35 | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.81.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.61 | -$1.76 | -$1.76 | -$1.76 | -$1.81 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.59 | -$1.71 | -$1.70 | -$1.75 | -$1.78 | N/A |
| Quarter ending Mar 31, 2027 | -$0.41 | -$0.43 | -$0.43 | -$0.44 | -$0.45 | N/A |
Frequently Asked Questions About SLDB
What is the SLDB stock forecast?
Consensus analyst estimates put Solid Biosciences LLC's EPS at -$1.61 for the fiscal year ending Dec 31, 2026. The consensus rating from 14 analysts is Buy.
How do analysts rate SLDB stock?
Of 14 analysts covering Solid Biosciences LLC, 5 rate it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SLDB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.61, with estimates from -$1.68 to -$1.58 from 12 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.59, with estimates from -$2.14 to -$1.34 from 14 analysts.
What revenue do analysts expect from Solid Biosciences LLC next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.75M.
How many analysts cover SLDB?
14 analysts rate Solid Biosciences LLC stock, and 12 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SLDB pages: Overview, Earnings, Forecast, Financials, Competitors